Cepharanthine Attenuates Pulmonary Fibrosis via Modulating Macrophage M2 Polarization

September 2024 in “ BMC Pulmonary Medicine ”

Jiaqi Bao, Chang Liu, Huafeng Song, Zheying Mao, Wenxin Qu, Fei Yu, Yifei Shen, Jingjing Jiang, Xi Chen, Ruonan Wang, Qi Wang, Weizhen Chen, Shu‐Fa Zheng, Yu Chen

Studysummary This study demonstrated that CEP may effectively treat pulmonary fibrosis by inhibiting fibroblast activation through regulating macrophage M2 polarization and decreasing fibrosis-associated factors, suggesting a new avenue for future research in this area.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on link.springer.com →

Discuss this study in the Community →

Research cited in this study

4 / 4 results

research Pharmacological Activity Of Cepharanthine

3 citations , June 2023 in “Molecules/Molecules online/Molecules annual”

The researchers reviewed cepharanthine, a long-used bisbenzylisoquinoline alkaloid, for its antiviral properties, including significant inhibition of SARS-CoV-2. They discussed cepharanthine's other pharmacological actions, highlighted plasma membrane fluidity as a key antiviral mechanism, and examined its safety, bioavailability, and potential for new clinical applications.

research Bioavailability Enhancement of Cepharanthine via Pulmonary Administration in Rats and Its Therapeutic Potential for Pulmonary Fibrosis Associated with COVID-19 Infection

14 citations , April 2022 in “Molecules”

This study found that pulmonary delivery of cepharanthine significantly improved bioavailability and may provide protective effects against pulmonary fibrosis related to COVID-19 infection in a rat model.

Comparison of Viral RNA–Host Protein Interactomes Across Pathogenic RNA Viruses Informs Rapid Antiviral Drug Discovery for SARS-CoV-2

research Comparison of Viral RNA–Host Protein Interactomes Across Pathogenic RNA Viruses Informs Rapid Antiviral Drug Discovery for SARS-CoV-2

100 citations , November 2021 in “Cell Research”

This study found that SARS-CoV-2 hijacks the host factor IGF2BP1 to stabilize its RNA and enhance translation, and identified Cepharanthine and Trifluoperazine as potential treatments against the virus.

research Cepharanthine: A Review of the Antiviral Potential of a Japanese-Approved Alopecia Drug in COVID-19

70 citations , July 2020 in “Pharmacological Reports”

This review discusses the antiviral potential of cepharanthine against SARS-CoV-2, noting its effectiveness in preclinical models but presenting no new clinical results.